


WHAT IS CLAIMED IS:

1. A compound of Formula (I):




(I)

or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:

R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;
R₂ is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, -NO₂, -N₃, -OH, -S(O)_kR₁₀₀, -OR₁₀₁, -NR₁₀₂R₁₀₃, -CONR₁₀₄R₁₀₅, -CO₂R₁₀₆ or -O₂CR₁₀₇;

R₃ and R₄ are independently hydrogen, deuterium, fluoro, hydroxy or methoxy;

R₅ is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₃) perfluoroalkyl;



R₇ is methyl, ethanyl, propan-1-yl, butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₈ is hydrogen, (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl, benzyl or substituted benzyl;

R₉ is methyl, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₁₀ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₀₈ or -CONR₁₀₉R₁₁₀;

R₁₁ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₁ or -CONR₁₁₂R₁₁₃;

5 R₁₂ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₄ or -CONR₁₁₅R₁₁₆;

R₁₃ is hydrogen or halogen;

R₁₀₁-R₁₁₆ are each independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;


10 and

k is 0, 1 or 2;

n is 0, 1, 2 or 3;

provided that:

15 a) when R₁ and R₅ are methyl, R₂, R₃, R₄, R₁₀, R₁₁, R₁₂ and R₁₃ are hydrogen




and R₆ is , that:

R₇ is not methyl, R₈ is not hydrogen and R₉ is not benzyl;

R₇ is not n-butyl, R₈ is not methyl and R₉ is not methyl; and

20 R₇ is not ethyl, R₈ is not hydrogen and R₉ is not isobutyl; or


b) when R₁ and R₅ are methyl, R₃ is -OCH₃, R₂, R₄, R₁₀, R₁₁, R₁₂ and R₁₃ are



hydrogen and R₆ is , that:

R₇ is not methyl, R₈ is not hydrogen and R₉ is not benzyl;

c) when R_1 and R_5 are methyl, $R_2, R_3, R_4, R_{10}, R_{11}$ and R_{12} are hydrogen, R_{13} is




bromine and R_6 is , that:

R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; and
 R_7 is not methyl, R_8 is not hydrogen and R_9 is not isopropyl; or

5


d) when R_1 and R_5 are methyl, $R_2, R_3, R_4, R_{10}, R_{11}$ and R_{12} are hydrogen, R_{13} is



iodine and R_6 is , that:

R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; or


10 e) when R_1 is methyl, R_5 is n-propyl, $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are



hydrogen and R_6 is , that:

R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; or

f) when $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are hydrogen and R_6 is




that:


R_1 is not allyl; or

15

g) when R_1 is (C₁-C₄) alkyl and $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are hydrogen,
that:




5 h) when R_1 is CH_2NHMe_2 , R_5 is methyl, $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are




R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; or

i) when R_1 is CH_2OH , R_5 is methyl, $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are




10 R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; or

j) when R_1 and R_5 are methyl and R_2, R_3 and R_4 are hydrogen, that R_6 is




15

k) when R_1 and R_5 are methyl and R_2, R_3 and R_4 are hydrogen, that R_6 is not




- 1) when R_1 and R_5 are methyl and R_2 , R_3 and R_4 are hydrogen, that R_6 is not




- 5 2. A compound of Formula (I) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 1, wherein:

- a) R_6 is




- 10 , R_7 is methyl or ethyl, R_8 is hydrogen or methyl, R_9 is n-propyl, isopropyl, isobutyl or benzyl, and R_{10} , R_{11} and R_{12} are hydrogen; or

- b) R_1 is (C_1-C_4) alkyl or (C_1-C_4) perfluoroalkyl and R_6 is




; or

- 15 c) R_1 is $-CH_3$, $-C_2H_5$, $-C_3H_7$, $i-C_3H_7$, $-CF_3$, $-C_2F_5$, $-C_3F_7$ or $i-C_3F_7$ and R_6 is



3. A compound of Formula (I) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 1, wherein in Formula (I):


- 5 a) R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $i\text{-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}_3\text{F}_7$ or $i\text{-C}_3\text{F}_7$, R_2 is $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_1\text{-C}_4)$ substituted alkyl, $(\text{C}_1\text{-C}_4)$ acyl, $(\text{C}_1\text{-C}_4)$ substituted acyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{O}_2\text{CR}_{107}$, n is 0 or 1, R_3 and R_4 are independently hydrogen or deuterium, R_5 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CF}_3$, C_2F_5 or $-\text{C}_3\text{F}_7$, R_6 is



, R_{10} , R_{11} and R_{12} are independently hydrogen, OH or $(\text{C}_1\text{-C}_4)$ alkyl; and R_{13} is hydrogen or bromine; or

10

- b) R_1 is CH_3 , $-\text{C}_2\text{H}_5$, $-\text{nC}_3\text{H}_7$, $-\text{CF}_3$, C_2F_5 or $-\text{nC}_3\text{F}_7$, R_2 is $(\text{C}_1\text{-C}_2)$ alkyl, $(\text{C}_1\text{-C}_2)$ substituted alkyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{O}_2\text{CR}_{107}$, n is 0; R_3 and R_4 are independently hydrogen or deuterium, R_5 is $-\text{CH}_3$ or $-\text{CF}_3$, R_6 is




15


, R_7 is methyl or ethyl, R_8 is hydrogen or methyl, R_9 is n -propyl, isopropyl, sec-butyl, isobutyl or benzyl, R_{10} , R_{11} and R_{12} are hydrogen; and R_{13} is hydrogen.

4. A compound of Formula (I) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 1, wherein the compound of Formula (I) is:






5. A compound of Formula (I) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 1, wherein the compound of Formula (I) is



6. A pharmaceutical composition comprising the compound of Formula (I) or pharmaceutically acceptable salt, hydrate or solvate thereof as defined in any one of the preceding claims and a pharmaceutically acceptable vehicle.

7. A compound of Formula (II):




or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:

R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

R₂ is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, -NO₂, -N₃, -OH, -S(O)_kR₁₀₀, -OR₁₀₁, -NR₁₀₂R₁₀₃, -CONR₁₀₄R₁₀₅, -CO₂R₁₀₆ or -O₂CR₁₀₇;

R₅ is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₃) alkyl, or (C₁-C₃) perfluoroalkyl;



R_7 is (C₁-C₄) alkyl;

5 R_8 is hydrogen, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, substituted (C₁-C₄) alkyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl, benzyl or substituted benzyl;

R_9 is methyl, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, butan-2-yl, 2-methyl-propan-2-yl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

10 R_{10} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₀₈ or -CONR₁₀₉R₁₁₀;

R_{11} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₁ or -CONR₁₁₂R₁₁₃;

R_{12} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₄ or -CONR₁₁₅R₁₁₆;

15 R_{13} is hydrogen or halogen;

R_{101} - R_{116} are each independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;


and

20 k is 0, 1 or 2;

n is 0, 1, 2 or 3;

provided that:

a) when R_1 and R_5 are methyl, R_2 , R_{10} , R_{11} , R_{12} and R_{13} are hydrogen and R_6 is



that:

R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl;

R_7 is not isopropyl, R_8 is not hydrogen and R_9 is not benzyl;


5 R_7 is not methyl, R_8 is not hydrogen and R_9 is not sec-butyl;

R_7 is not ethyl, R_8 is not hydrogen and R_9 is not isopropyl;

R_7 is not isopropyl, R_8 is not hydrogen and R_9 is not isopropyl;

R_7 is not ethyl, R_8 is not hydrogen and R_9 is not benzyl; or


10 b) when R_1 is allyl, R_5 is methyl, R_2 , R_{10} , R_{11} , R_{12} and R_{13} are hydrogen and R_6 is



that:

R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; or

c) when R_1 is CH_2OH , R_5 is methyl, R_2 , R_{10} , R_{11} , R_{12} and R_{13} are hydrogen and




15 R_6 is

that:

R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl; or

- d) when R_1 is CH_2OH , R_5 is methyl, R_2 , R_{10} , R_{11} , and R_{12} are hydrogen, R_{13} is




bromine and R_6 is


that:

R_7 is not isopropyl, R_8 is not hydrogen and R_9 is not sec-butyl.

- 5 8. A compound of Formula (II) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 7, wherein:




- a) R_6 is , R_7 is methyl, ethyl or isopropyl, R_8 is hydrogen, R_9 is n-propyl, isopropyl, sec-butyl, or benzyl and R_{10} , R_{11} and R_{12} are hydrogen; or



- b) R_1 is $(\text{C}_1\text{-C}_4)$ alkyl or $(\text{C}_1\text{-C}_4)$ perfluoroalkyl and R_6 is


; or

- c) R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $i\text{-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}_3\text{F}_7$ or $i\text{-C}_3\text{F}_7$ and R_6 is



9. A compound of Formula (II) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 7, wherein in Formula (II):


a) R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $i\text{-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}_3\text{F}_7$ or $i\text{-C}_3\text{F}_7$, R_2 is $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_1\text{-C}_4)$ substituted alkyl, $(\text{C}_1\text{-C}_4)$ acyl, $(\text{C}_1\text{-C}_4)$ substituted acyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{O}_2\text{CR}_{107}$, n is 0 or 1, R_5 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CF}_3$,



C_2F_5 or $-\text{C}_3\text{F}_7$, R_6 is , R_{10} , R_{11} and R_{12} are independently hydrogen, OH or

5 $(\text{C}_1\text{-C}_4)$ alkyl; and R_{13} is hydrogen or bromine; or



b) R_1 is CH_3 , $-\text{C}_2\text{H}_5$, $-\text{nC}_3\text{H}_7$, $-\text{CF}_3$, C_2F_5 or $-\text{nC}_3\text{F}_7$, R_2 is $(\text{C}_1\text{-C}_2)$ alkyl, $(\text{C}_1\text{-C}_2)$ substituted alkyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{O}_2\text{CR}_{107}$; n is





0, R_5 is $-\text{CH}_3$ or $-\text{CF}_3$; R_6 is , R_7 is methyl, ethyl or isopropyl, R_8 is

10 hydrogen, R_9 is n -propyl, isopropyl, sec-butyl, or benzyl; R_{10} , R_{11} and R_{12} are hydrogen; and R_{13} is hydrogen.

10. A compound of Formula (II) or pharmaceutically acceptable salt, hydrate or solvate thereof according to claim 7, wherein the compound of Formula (II) is:




or




Z is 5 or 8.

5




or



11. A pharmaceutical composition comprising the compound of Formula (II) or pharmaceutically acceptable salt, hydrate or solvate thereof as defined in any one of claims 7 to 10 and a pharmaceutically acceptable vehicle.

10

12. Use of a compound of Formula (I):



(I)

or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:


R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

5 R₂ is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, -NO₂, -N₃, -OH, -S(O)_kR₁₀₀, -OR₁₀₁, -NR₁₀₂R₁₀₃, -CONR₁₀₄R₁₀₅, -CO₂R₁₀₆ or -O₂CR₁₀₇;

R₃ and R₄ are independently hydrogen, deuterium, fluoro, hydroxy or methoxy;

R₅ is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₃) perfluoroalkyl;

10



R₇ is methyl, ethanyl, propan-1-yl, butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₈ is hydrogen, (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl, benzyl or substituted benzyl;

15

R₉ is methyl, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₁₀ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₀₈ or -CONR₁₀₉R₁₁₀;

R_{11} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₁ or -CONR₁₁₂R₁₁₃;

R_{12} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₄ or -CONR₁₁₅R₁₁₆;

5 R_{13} is hydrogen or halogen;


R_{101} - R_{116} are each independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and

10 k is 0, 1 or 2;

n is 0, 1, 2 or 3;

provided that:


a) when $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are hydrogen and R_6 is



15 that:

R_1 is not allyl; or


b) when R_1 and R_5 are methyl, $R_2, R_3, R_4, R_{10}, R_{11}, R_{12}$ and R_{13} are hydrogen and



R_6 is that: R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl;

20 in the manufacture of a medicament for treating or preventing migraine in a patient.

13. Use of a compound of Formula (I):



(I)


or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:

R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

5 R₂ is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, -NO₂, -N₃, -OH, -S(O)_kR₁₀₀, -OR₁₀₁, -NR₁₀₂R₁₀₃, -CONR₁₀₄R₁₀₅, -CO₂R₁₀₆ or -O₂CR₁₀₇;

R₃ and R₄ are independently hydrogen, deuterium, fluoro, hydroxy or methoxy;

R₅ is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₃) perfluoroalkyl;



10 R₇ is methyl, ethanyl, propan-1-yl, butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₈ is hydrogen, (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl, benzyl or substituted benzyl;

15 R₉ is methyl, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₁₀ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₀₈ or -CONR₁₀₉R₁₁₀;

R_{11} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₁ or -CONR₁₁₂R₁₁₃;

R_{12} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₄ or -CONR₁₁₅R₁₁₆;

5 R_{13} is hydrogen or halogen;

R_{101} - R_{116} are each independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and


10 k is 0, 1 or 2;

n is 0, 1, 2 or 3;

in the manufacture of a medicament for treating or preventing ALS, Parkinson's disease, extra-pyramidal disorders, depression, nausea, restless legs syndrome, insomnia, aggression, Huntington's disease, dystonia, parsomnia or hyperlactinemia in a patient.

15

14. Use of a compound of Formula (I):



(I)

or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:


R_1 is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

20

R_2 is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, -NO₂, -N₃, -OH, -S(O)_kR₁₀₀, -OR₁₀₁, -NR₁₀₂R₁₀₃, -CONR₁₀₄R₁₀₅, -CO₂R₁₀₆ or -O₂CR₁₀₇;

R_3 and R_4 are independently hydrogen, deuterium, fluoro, hydroxy or methoxy;

R_5 is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₃) perfluoroalkyl;



R₇ is methyl, ethanyl, propan-1-yl, butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

5 R₈ is hydrogen, (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl, benzyl or substituted benzyl;

R₉ is methyl, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₁₀ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₀₈ or -CONR₁₀₉R₁₁₀;

10 R₁₁ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₁ or -CONR₁₁₂R₁₁₃;

R₁₂ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₄ or -CONR₁₁₅R₁₁₆;

R₁₃ is hydrogen or halogen;

15 R₁₀₁-R₁₁₆ are each independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and


k is 0, 1 or 2;

20 n is 0, 1, 2 or 3;

in the manufacture of a medicament for treating or preventing migraine, ALS, Parkinson's disease, extra-pyramidal disorders, depression, nausea, restless legs syndrome, insomnia, aggression, Huntington's disease, dystonia, parasomnia or hyperlactinemia in a patient, optionally wherein the dose range is between 0.1 mg and 100 mg.

25

15. Use of a compound of Formula (II):




(II)

or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:

R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

R₂ is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, -NO₂, -N₃, -OH, -S(O)_kR₁₀₀, -OR₁₀₁, -NR₁₀₂R₁₀₃, -CONR₁₀₄R₁₀₅, -CO₂R₁₀₆ or -O₂CR₁₀₇;

R₅ is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₃) alkyl, or (C₁-C₃) perfluoroalkyl;



R₇ is (C₁-C₄) alkyl;

R₈ is hydrogen, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, butan-2-yl, 2-methylpropan-1-yl, 2-methylpropan-2-yl, substituted (C₁-C₄) alkyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl, benzyl or substituted benzyl;

R₉ is methyl, ethanyl, propan-1-yl, propan-2-yl, butan-1-yl, butan-2-yl, 2-methylpropan-2-yl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₁₀ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₀₈ or -CONR₁₀₉R₁₁₀;

R₁₁ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₁ or -CONR₁₁₂R₁₁₃;

R₁₂ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, -CO₂R₁₁₄ or -CONR₁₁₅R₁₁₆;

R₁₃ is hydrogen or halogen;

5 R₁₀₁-R₁₁₆ are each independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and


k is 0, 1 or 2;

n is 0, 1, 2 or 3;

10 in the manufacture of a medicament for treating or preventing migraine, ALS, Parkinson's disease, extra-pyramidal disorders, depression, nausea, restless legs syndrome, insomnia, aggression, Huntington's disease, dystonia, parasomnia or hyperlactinemia in a patient.

What is claimed is:

1. A compound of Formula (I):



or pharmaceutically acceptable salts, hydrates or solvates thereof wherein:






R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

R₂ is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, —NO₂, —N₃, —OH, —S(O)_kR₁₀₀, —OR₁₀₁, —NR₁₀₂R₁₀₃, —CONR₁₀₄R₁₀₅, —CO₂R₁₀₆ or —OC(O)R₁₀₇;

R₃ and R₄ are independently hydrogen, deuterium, fluoro, hydroxy or methoxy;

R₅ is hydrogen, (C₁-C₃) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₃) perfluoroalkyl;

R₆ is



R_7 is sec-butyl, isobutyl, t-butyl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R_8 is hydrogen, (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl, benzyl or substituted benzyl;

R_9 is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, benzyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R_{10} is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, —CO₂R₁₀₈ or —CONR₁₀₉R₁₁₀;

R₁₁ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, —CO₂R₁₁₁ or —CONR₁₁₂R₁₁₃;

R₁₂ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, —CO₂R₁₁₄ or —CONR₁₁₅R₁₁₆;

R₁₃ is hydrogen or halogen;


R₁₀₁, R₁₀₂, R₁₀₃, R₁₀₄, R₁₀₅, R₁₀₆, R₁₀₇, R₁₀₈, R₁₀₉, R₁₁₀, R₁₁₁, R₁₁₂, R₁₁₃, R₁₁₄, R₁₁₅ and R₁₁₆ are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and

k is 0, 1 or 2;

n is 0, 1, 2 or 3;

wherein substituted with reference to a saturated carbon atom is limited to —R^a, halo, —O[−], =O, —OR^b, —SR^b, —S[−], =S, —NR^cR^c, =NR^b, =N—OR^b, trihalomethyl, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂, =N₂, —N₃, —S(O)₂R^b, —S(O)₂NR^b, —S(O)₂O[−], —S(O)₂OR^b, —OS(O)₂R^b, —OS(O)₂O[−], —OS(O)₂OR^b, —P(O)(O[−])₂, —P(O)(OR^b)(O[−]), —P(O)(OR^b)(OR^b), —C(O)R^b, —C(S)R^b, —C(NR^b)R^b, —C(O)O[−], —C(O)OR^b, —C(S)OR^b, —C(O)NR^cR^c, —C(NR^b)NR^cR^c, —OC(O)R^b, —OC(S)R^b, —OC(O)O[−], —OC(O)OR^b, —OC(S)OR^b, —NR^bC(O)R^b, —NR^bC(S)R^b, —NR^bC(O)O[−], —NR^bC(O)OR^b, —NR^bC(S)OR^b, —NR^bC(O)NR^cR^c, —NR^bC(NR^b)R^b and —NR^bC(NR^b)NR^cR^c, where R^a is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; each R^b is independently hydrogen or R^a; and each R^c is independently R^b or alternatively, the two R^cs are taken together with the nitrogen atom to which they are bonded form a 4-, 5-, 6- or 7-membered cycloheteroalkyl which may optionally include from 1 to 4 of the same or different additional heteroatoms selected from the group consisting of O, N and S; and substituted with reference to an unsaturated carbon atom or an nitrogen atom in a heteroalkyl group is limited to —R^a, halo, —O[−], —OR^b, —SR^b, —S[−], —NR^cR^c, trihalomethyl, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂, —N₃, —S(O)₂R^b, —S(O)₂O[−], —S(O)₂OR^b, —OS(O)₂R^b, —OS(O)₂O[−], —OS(O)₂OR^b, —P(O)(O[−])₂, —P(O)(OR^b)(O[−]), —P(O)(OR^b)(OR^b), —C(O)R^b, —C(S)R^b, —C(NR^b)R^b, —C(O)O[−], —C(O)OR^b, —C(S)OR^b, —C(O)NR^cR^c, —C(NR^b)NR^cR^c, —OC(O)R^b, —

OC(S)R^b , —OC(O)O^- , —OC(O)OR^b , —OC(S)OR^b , $\text{—NR}^b\text{C(O)R}^b$, $\text{—NR}^b\text{C(S)R}^b$, $\text{—NR}^b\text{C(O)O}^-$, $\text{—NR}^b\text{C(O)OR}^b$, $\text{—NR}^b\text{C(S)OR}^b$, $\text{—NR}^b\text{C(O)NR}^c\text{R}^c$, $\text{—NR}^b\text{C(NR}^b\text{)R}^b$ and $\text{—NR}^b\text{C(NR}^b\text{)NR}^c\text{R}^c$ where R^a , R^b and R^c are as defined above;




provided that when R_2 , R_3 , R_4 , R_{10} , R_{11} , R_{12} and R_{13} are hydrogen and R_6 is O that:



R_1 is not allyl;

provided that when R_1 is $(\text{C}_1\text{—C}_4)$ alkyl and R_2 , R_3 , R_4 , R_{10} , R_{11} , R_{12} and R_{13} are hydrogen that:


R_6 is not




provided that when R_1 and R_5 are methyl and R_2 , R_3 and R_4 are hydrogen that: R_6 is not




provided that when R_1 and R_5 are methyl and R_2 , R_3 and R_4 are hydrogen that: R_6 is not




provided that when R_1 and R_5 are methyl and R_2 , R_3 and R_4 are hydrogen that: R_6 is not




2. The compound of claim 1, wherein R_1 is (C_1-C_4) alkyl or (C_1-C_4) perfluoroalkyl and R_6 is



3. The compound of claim 1, wherein R_1 is $-CH_3$, $-C_2H_5$, $-C_3H_7$, $i-C_3H_7$, $-CF_3$, $-C_2F_5$, $-C_3F_7$ or $i-C_3F_7$ and R_6 is




4. The compound of claim 1, wherein R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $i\text{-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}_3\text{F}_7$ or $i\text{-C}_3\text{F}_7$, R_2 is $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_1\text{-C}_4)$ substituted alkyl, $(\text{C}_1\text{-C}_4)$ acyl, $(\text{C}_1\text{-C}_4)$ substituted acyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{OC(O)}\text{R}_{107}$, n is 0 or 1, R_3 and R_4 are independently hydrogen or deuterium, R_5 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CF}_3$, C_2F_5 or $-\text{C}_3\text{F}_7$, R_6 is




R_{10} , R_{11} and R_{12} are independently hydrogen, OH or $(\text{C}_1\text{-C}_4)$ alkyl; and R_{13} is hydrogen or bromine.


5. The compound of claim 1 having the structure:



6. The compound of claim 1 having the structure:




or



wherein z is 5 or 8.

7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable vehicle.


8. A compound of Formula (II):



R₁ is (C₁-C₄) alkyl, substituted (C₁-C₄) alkyl or (C₁-C₄) perfluoroalkyl;

—NO₂, —N₃, —OH, —S(O)_kR₁₀₀, —OR₁₀₁, —NR₁₀₂R₁₀₃, —CONR₁₀₄R₁₀₅, —CO₂R₁₀₆ or —OC(O)R₁₀₇;

R_6 is



R₈ is hydrogen, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, substituted (C₁-yl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl, benzyl or substituted benzyl;

R₉ is methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, (C₂-C₄) alkenyl or (C₂-C₄) alkynyl;

R₁₀ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, —CO₂R₁₀₈ or —CONR₁₀₉R₁₁₀;

R₁₁ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, —CO₂R₁₁₁ or —CONR₁₁₂R₁₁₃;

R₁₂ is hydrogen, OH, =O, (C₁-C₄) alkyl, (C₁-C₄) substituted alkyl, —CO₂R₁₁₄ or —CONR₁₁₅R₁₁₆;

R₁₃ is hydrogen or halogen;

R₁₀₁, R₁₀₂, R₁₀₃, R₁₀₄, R₁₀₅, R₁₀₆, R₁₀₇, R₁₀₈, R₁₀₉, R₁₁₀, R₁₁₁, R₁₁₂, R₁₁₃, R₁₁₄, R₁₁₅ and R₁₁₆ are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; and


k is 0, 1 or 2;

n is 0, 1, 2 or 3;

wherein substituted with reference to a saturated carbon atom is limited to —R^a, halo, —O[−], =O, —OR^b, —SR^b, —S[−], =S, —NR^cR^c, =NR^b, =N—OR^b, trihalomethyl, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂, =N₂, —N₃, —S(O)₂R^b, —S(O)₂NR^b, —S(O)₂O[−], —S(O)₂OR^b, —OS(O)₂R^b, —OS(O)₂O[−], —OS(O)₂OR^b, —P(O)(O[−])₂, —P(O)(OR^b)(O[−]), —P(O)(OR^b)(OR^b), —C(O)R^b, —C(S)R^b, —C(NR^b)R^b, —C(O)O[−], —C(O)OR^b, —C(S)OR^b, —C(O)NR^cR^c, —C(NR^b)NR^cR^c, —OC(O)R^b, —OC(S)R^b, —OC(O)O[−], —OC(O)OR^b, —OC(S)OR^b, —NR^bC(O)R^b, —NR^bC(S)R^b, —NR^bC(O)O[−], —NR^bC(O)OR^b, —NR^bC(S)OR^b, —NR^bC(O)NR^cR^c, —NR^bC(NR^b)R^b and —NR^bC(NR^b)NR^cR^c, where R^a is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; each R^b is independently hydrogen or R^a; and each R^c is independently R^b or alternatively, the two R^cs are taken together with the nitrogen atom to which they are bonded form a 4-, 5-, 6- or 7-membered cycloheteroalkyl which may optionally include from 1 to 4 of the same or different additional heteroatoms selected from the group consisting of O, N and S; and substituted with reference to an unsaturated carbon atom or an nitrogen atom in a heteroalkyl

group is limited to $-\text{R}^a$, halo, $-\text{O}^-$, $-\text{OR}^b$, $-\text{SR}^b$, $-\text{S}^-$, $-\text{NR}^c\text{R}^c$, trihalomethyl, $-\text{CF}_3$, $-\text{CN}$, $-\text{OCN}$, $-\text{SCN}$, $-\text{NO}$, $-\text{NO}_2$, $-\text{N}_3$, $-\text{S}(\text{O})_2\text{R}^b$, $-\text{S}(\text{O})_2\text{O}^-$, $-\text{S}(\text{O})_2\text{OR}^b$, $-\text{OS}(\text{O})_2\text{R}^b$, $-\text{OS}(\text{O})_2\text{O}^-$, $-\text{OS}(\text{O})_2\text{OR}^b$, $-\text{P}(\text{O})(\text{O}^-)_2$, $-\text{P}(\text{O})(\text{OR}^b)(\text{O}^-)$, $-\text{P}(\text{O})(\text{OR}^b)(\text{OR}^b)$, $-\text{C}(\text{O})\text{R}^b$, $-\text{C}(\text{S})\text{R}^b$, $-\text{C}(\text{NR}^b)\text{R}^b$, $-\text{C}(\text{O})\text{O}^-$, $-\text{C}(\text{O})\text{OR}^b$, $-\text{C}(\text{S})\text{OR}^b$, $-\text{C}(\text{O})\text{NR}^c\text{R}^c$, $-\text{C}(\text{NR}^b)\text{NR}^c\text{R}^c$, $-\text{OC}(\text{O})\text{R}^b$, $-\text{OC}(\text{S})\text{R}^b$, $-\text{OC}(\text{O})\text{O}^-$, $-\text{OC}(\text{O})\text{OR}^b$, $-\text{OC}(\text{S})\text{OR}^b$, $-\text{NR}^b\text{C}(\text{O})\text{R}^b$, $-\text{NR}^b\text{C}(\text{S})\text{R}^b$, $-\text{NR}^b\text{C}(\text{O})\text{O}^-$, $-\text{NR}^b\text{C}(\text{O})\text{OR}^b$, $-\text{NR}^b\text{C}(\text{S})\text{OR}^b$, $-\text{NR}^b\text{C}(\text{O})\text{NR}^c\text{R}^c$, $-\text{NR}^b\text{C}(\text{NR}^b)\text{R}^b$ and $-\text{NR}^b\text{C}(\text{NR}^b)\text{NR}^c\text{R}^c$ where R^a , R^b and R^c are as defined above;

provided that when R_1 and R_5 are methyl, R_2 , R_{10} , R_{11} , R_{12} and R_{13} are hydrogen and R_6 is



that:


R_7 is not methyl, R_8 is not hydrogen and R_9 is not benzyl;

R_7 is not methyl, R_8 is not hydrogen and R_9 is not sec-butyl;

R_7 is not ethyl, R_8 is not hydrogen and R_9 is not isopropyl;

R_7 is not isopropyl, R_8 is not hydrogen and R_9 is not isopropyl;


provided that when R_1 is CH_2OH , R_5 is methyl, R_2 , R_{10} , R_{11} , and R_{12} are hydrogen, R_{13} is bromine and R_6 is



that:


R_7 is not isopropyl, R_8 is not hydrogen and R_9 is not sec-butyl.

9. The compound of claim 8, wherein R_6 is




R_7 is methyl, ethyl or isopropyl, R_8 is hydrogen, R_9 is n-propyl, isopropyl or sec-butyl and R_{10} , R_{11} and R_{12} are hydrogen.

10. The compound of claim 8, wherein R_1 is (C_1-C_4) alkyl or (C_1-C_4) perfluoroalkyl and R_6 is




11. The compound of claim 8, wherein R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $i\text{-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}_3\text{F}_7$ or $i\text{-C}_3\text{F}_7$ and R_6 is




12. The compound of claim 8, wherein R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $i\text{-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}_3\text{F}_7$ or $i\text{-C}_3\text{F}_7$, R_2 is (C_1-C_4) alkyl, (C_1-C_4) substituted alkyl, (C_1-C_4) acyl, (C_1-C_4) substituted

acyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{OC(O)}\text{R}_{107}$, n is 0 or 1, R_5 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CF}_3$, C_2F_5 or $-\text{C}_3\text{F}_7$, R_6 is






R_{10} , R_{11} and R_{12} are independently hydrogen, OH or $(\text{C}_1\text{-C}_4)$ alkyl; and R_{13} is hydrogen or bromine.




13. The compound of claim 8, wherein R_1 is $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{n-C}_3\text{H}_7$, $-\text{CF}_3$, $-\text{C}_2\text{F}_5$ or $-\text{n-C}_3\text{F}_7$, R_2 is $(\text{C}_1\text{-C}_2)$ alkyl, $(\text{C}_1\text{-C}_2)$ substituted alkyl, halo, $-\text{NO}_2$, $-\text{OR}_{101}$, $-\text{NR}_{102}\text{R}_{103}$, $-\text{CONR}_{104}\text{R}_{105}$, $-\text{CO}_2\text{R}_{106}$ or $-\text{OC(O)}\text{R}_{107}$, n is 0, R_5 is $-\text{CH}_3$ or $-\text{CF}_3$, R_6 is





R_7 is methyl, ethyl or isopropyl, R_8 is hydrogen, R_9 is n -propyl, isopropyl, sec -butyl, or benzyl, R_{10} , R_{11} and R_{12} are hydrogen; and R_{13} is hydrogen.


14. The compound of claim 8, having the structure:









15. The compound of claim 8, having structure:





16. The compound of claim 8 having the structure:




or



17. The compound of claim 8, having the structure:



or



wherein z is 5 or 8.

18. A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically acceptable vehicle.

19. The compound having the structure:

